Loading…
RedHill Biopharma Ltd. is projected to rise to $0.7605 by 2027, a +9% move from its current price of $0.695. RDHL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.6681 | $0.6956 | $0.7243 | +0.09% |
| Jul 15 | $0.6576 | $0.6963 | $0.7373 | +0.18% |
| Jul 16 | $0.6498 | $0.6969 | $0.7475 | +0.28% |
| Jul 17 | $0.6434 | $0.6976 | $0.7563 | +0.37% |
| Jul 18 | $0.6379 | $0.6982 | $0.7643 | +0.46% |
| Jul 19 | $0.633 | $0.6989 | $0.7716 | +0.56% |
| Jul 20 | $0.6285 | $0.6995 | $0.7785 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6285 | $0.6995 | $0.7785 | +0.65% |
| Week 2 | $0.6052 | $0.704 | $0.819 | +1.30% |
| Week 3 | $0.5887 | $0.7086 | $0.8529 | +1.96% |
| Week 4 | $0.5758 | $0.7132 | $0.8834 | +2.62% |
| Week 5 | $0.5651 | $0.7178 | $0.9118 | +3.28% |
| Week 6 | $0.5559 | $0.7225 | $0.9389 | +3.95% |
| Week 7 | $0.5479 | $0.7272 | $0.9651 | +4.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company that focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its pipeline consists of five therapeutic candidates in clinical development, including opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
RDHL currently trades at $0.71 per share and has a market capitalization of $4.32M. Its rank is 5355 among listed stocks.
The price outlook for RDHL shows a path of gradual upside in the coming years, with the forecasted average price rising from $0.71 in 2026 to about $0.7712 in 2027, $0.9046 in 2028, and $1.08 in 2029, before settling around $0.9619 in 2030. The long-range view projects further growth to an average of $1.53 by 2040 and $2.39 by 2050, with max values up to $3.05 in 2040 and $5.36 in 2050."
A major floor 32.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 48.2% above — a clean break opens room to run.
A major ceiling 64.3% above — clearing it would confirm fresh momentum.
Key RDHL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RDHL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7266 | Sell | $0.7279 | Sell |
| MA 10 | $0.7859 | Sell | $0.7668 | Sell |
| MA 20 | $0.8173 | Sell | $0.8144 | Sell |
| MA 50 | $0.9241 | Sell | $0.8781 | Sell |
| MA 100 | $0.9053 | Sell | $0.9528 | Sell |
| MA 200 | $1.12 | Sell | $1.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.19 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -154.50 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -24.95 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.67 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 14.76 | Buy |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.67 | Buy |
| ADX (14) | 20.73 | Sell |
| ATR (14) | 0.03 | Info |
The near-term technical picture shows bearish momentum.
The 30-day range for RDHL is $0.5348 to $0.9426, and the current price is $0.71, sitting at the established support of $0.71. RSI14 is 30, indicating potential weakness in the short term. The stock is trading below its SMA50 of $0.9376 and SMA200 of $1.13, reinforcing the cautious near-term stance.
Resistance is identified at $1.03, suggesting a hurdle for upside in the coming weeks while near-term support sits at $0.71.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.695 | $0.695 | $0.9656 | 0% | Neutral | |
| $0.5784 | $0.7605 | $1.07 | +9% | Neutral | |
| $0.6423 | $0.8821 | $1.31 | +27% | Bullish | |
| $0.728 | $1.04 | $1.60 | +49% | Bullish | |
| $0.6401 | $0.9423 | $1.50 | +36% | Bullish | |
| $0.5629 | $0.854 | $1.40 | +23% | Bullish | |
| $0.5578 | $0.8708 | $1.47 | +25% | Bullish | |
| $0.586 | $0.9399 | $1.62 | +35% | Bullish | |
| $0.7245 | $1.19 | $2.10 | +72% | Bullish | |
| $0.7325 | $1.24 | $2.22 | +78% | Bullish | |
| $0.7918 | $1.50 | $2.92 | +116% | Bullish | |
| $1.06 | $2.36 | $5.14 | +239% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.695 | $0.695 | $0.8219 | +0.00% |
| August 2026 | $0.5909 | $0.7065 | $0.8738 | +1.65% |
| September 2026 | $0.6257 | $0.756 | $0.9502 | +7.01% |
| October 2026 | $0.6132 | $0.7477 | $0.9525 | -1.11% |
| November 2026 | $0.5885 | $0.7231 | $0.9316 | -3.28% |
| December 2026 | $0.5994 | $0.7418 | $0.9656 | +2.58% |
Click any year to see its month-by-month RDHL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
RedHill Biopharma Ltd.'s 2026 outlook centres on $0.695, within a $0.695 to $0.9656 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RDHL could reach as high as $1.07, with a base case around $0.7605 and support toward $0.5784 — roughly +9% from $0.695. Price action looks broadly range-bound.
Expect RDHL to range from $0.6423 to $1.31 through 2028. The $0.8821 average target implies a +27% move from current prices. That is up +16% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RDHL price prediction for 2029 points to an average of $1.04 (low $0.728, high $1.60) — a potential gain of +49% on today's $0.695. Momentum favours further upside here.
In 2030, RDHL is projected to trade between $0.6401 and $1.50, averaging $0.9423 — a potential gain of +36% from today's $0.695. That is -9% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
RedHill Biopharma Ltd.'s 2031 outlook centres on $0.854, within a $0.5629 to $1.40 range. That is -9% versus the projected 2030 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2032, RDHL could reach as high as $1.47, with a base case around $0.8708 and support toward $0.5578 — roughly +25% from $0.695. Buyers look set to stay in control over this stretch.
Expect RDHL to range from $0.586 to $1.62 through 2033. The $0.9399 average target implies a +35% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The RDHL price prediction for 2034 points to an average of $1.19 (low $0.7245, high $2.10) — a potential gain of +72% on today's $0.695. Buyers look set to stay in control over this stretch.
In 2035, RDHL is projected to trade between $0.7325 and $2.22, averaging $1.24 — a potential gain of +78% from today's $0.695. That is up +4% on the projected 2034 average. Momentum favours further upside here.
RedHill Biopharma Ltd.'s 2040 outlook centres on $1.50, within a $0.7918 to $2.92 range. That is up +22% on the projected 2035 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RDHL could reach as high as $5.14, with a base case around $2.36 and support toward $1.06 — roughly +239% from $0.695. Momentum favours further upside here.
Investing $1,000 in RDHL today (≈ 1,438.848921 RDHL) could be worth
$3,394.39
+$2,394.39 (+239%) by 2050 · US Dollar
Based on the average projected RDHL price of $2.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RDHLwould be worth at today's price.
$1,000 invested in RDHL on Jul 10, 2025 (≈ 469.483543 RDHL) would be worth
$326.29
-$673.71 (-67.4%) today · 0.33× · US Dollar
Based on a RDHL entry price of $2.13 vs. today's $0.695.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.812 | $855.91 | -14.4% |
| 1 month ago | $0.88 | $789.77 | -21.0% |
| 3 months ago | $0.825 | $842.42 | -15.8% |
| 6 months ago | $1.27 | $547.24 | -45.3% |
| 1 year ago | $2.13 | $326.29 | -67.4% |
| All time (5.0y) ago | $6,220 | $0.11 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RDHL forecast.
Our base-case forecast reaches $1.40 around 2040.
Implied market cap at $1.40: $8.51M
The multi-year forecast paints a bullish longer-term path despite near-term volatility. By 2027 the average price is projected at $0.7712 with a modest 8.6% return, turning more decisively bullish thereafter as the average climbs toward $0.9046 in 2028 and $1.08 in 2029, with a 51.8% ROI. The outlook remains bullish through 2030 (avg $0.9619, ROI 35.5%), 2031 (avg $0.8645, ROI 21.8%), and 2032 (avg $0.889, ROI 25.2%).
The forecast proceeds with stronger upside into 2033 ($0.9464 avg, 33.3% ROI) and 2034 ($1.22 avg, 71.5% ROI), then further into 2035 ($1.27 avg, 79.1% ROI). By 2040, the average price is projected at $1.53 with a 115.6% ROI, and by 2050 the average reaches $2.39 with a 236.6% ROI. The sentiment is bullish from 2028 onward.
These figures are estimates and not guarantees. Investors should consider the potential for volatility and the inherent uncertainty in long-horizon projections when evaluating a position in RDHL.
Tap a question to reveal the answer.
2030 forecast: min $0.6417, avg $0.9619, max $1.56; ROI 35.5%; sentiment BULLISH.
The forecast shows near-term neutrality in 2026 (avg $0.71) and 2027 (avg $0.7712), with bullish potential emerging from 2028 onward (avg $0.9046, ROI 27.4% in 2028; avg $1.08, ROI 51.8% in 2029). Long-term outlook remains bullish through 2050 (avg $2.39, ROI 236.6%). Keep in mind these are estimates, not guarantees.
2034 max $2.19; 2035 max $2.33; so reaching $2 is possible by 2034-2035 according to the forecast.
The 30-day range is $0.5348 to $0.9426. The current price is $0.71, with support at $0.71 and resistance at $1.03. RSI14 is 30, indicating bearish momentum, and the price is below the SMA50 ($0.9376) and SMA200 ($1.13).
2030 avg $0.9619; 2040 avg $1.53; 2050 avg $2.39 with max $5.36 and ROI 236.6%. The sentiment is BULLISH.
RedHill Biopharma Ltd. Community Discussion
0Share your RedHill Biopharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.